These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17180945)

  • 1. [Implanted cardioverters-defibrillators in the treatment of arrhythmias and prevention of sudden death].
    Bokeriia LA; Revishvili ASh; Neminushchiĭ NM; Lomidze NN
    Ter Arkh; 2006; 78(10):76-80. PubMed ID: 17180945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Implantable cardioverter-defibrillators in the prevention of sudden cardiac death].
    Kozák M; Krivan L; Semrád B
    Vnitr Lek; 2001 Jun; 47(6):361-70. PubMed ID: 11494881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A; Małecka L; Pytkowski M; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Ruzyłło W; Szwed H
    Kardiol Pol; 2005 Oct; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up and risk assessment of arrhythmogenic right ventricular dysplasia/cardiomyopathy: personal experience from different primary and tertiary centres.
    Peters S
    J Cardiovasc Med (Hagerstown); 2007 Jul; 8(7):521-6. PubMed ID: 17568286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillators in children.
    Werner B; Przybylski A; Kucińska B; Lewandowski M; Szwed H; Wróblewska-Kałuzewska M
    Kardiol Pol; 2004 Mar; 60(3):239-46. PubMed ID: 15156219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator recipients: long-term follow-up of the Leiden out-of-hospital cardiac arrest study (LOHCAT).
    Borleffs CJ; van Erven L; Schotman M; Boersma E; Kiès P; van der Burg AE; Zeppenfeld K; Bootsma M; van der Wall EE; Bax JJ; Schalij MJ
    Eur Heart J; 2009 Jul; 30(13):1621-6. PubMed ID: 19493865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
    Maron BJ; Spirito P
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implantable defibrillators in the management of malignant ventricular tachyarrhythmias. Experience at the Arrhythmia National Center].
    Asenjo R; Oyarzún R; González M; Morales P; Zamorano J; Brunet L; Morris R; Ortiz M
    Rev Med Chil; 1998 Jul; 126(7):803-13. PubMed ID: 9830773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmogenic right ventricular dysplasia: a United States experience.
    Dalal D; Nasir K; Bomma C; Prakasa K; Tandri H; Piccini J; Roguin A; Tichnell C; James C; Russell SD; Judge DP; Abraham T; Spevak PJ; Bluemke DA; Calkins H
    Circulation; 2005 Dec; 112(25):3823-32. PubMed ID: 16344387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of ventricular tachyarrhythmia with implantable cardioverters/defibrillators--mortality and complications using epicardial electrodes].
    Wietholt D; Block M; Isbruch F; Böcker D; Hammel D; Borggrefe M; Scheld HH; Breithardt G
    Z Kardiol; 1993 Mar; 82(3):150-61. PubMed ID: 8475651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
    Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
    Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G; Nishimura RA; Gersh BJ; Phil D; Ommen SR; Ackerman MJ; Brady PA
    Heart; 2009 May; 95(9):709-14. PubMed ID: 19282314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter defibrillator (ICD) in children.
    Eicken A; Kolb C; Lange S; Brodherr-Heberlein S; Zrenner B; Schreiber C; Hess J
    Int J Cardiol; 2006 Feb; 107(1):30-5. PubMed ID: 16337494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and characteristics of appropriate and inappropriate therapies in recipients of ICD implanted for primary prevention of sudden cardiac death.
    Kreuz J; Balta O; Liliegren N; Mellert F; Esmailzadeh B; Nickenig G; Schwab JO
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S125-7. PubMed ID: 17302687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.